You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Drug Price Trends for NDC 71093-0138


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 71093-0138

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 71093-0138

Last updated: March 2, 2026

What Is NDC 71093-0138?

NDC 71093-0138 is the National Drug Code identifier for a specific drug product. Based on available data, this code corresponds to Bupropion Hydrochloride Extended-Release (SR) 100 mg, manufactured by a generic producer. This formulation is used primarily for depression and smoking cessation.

Market Overview

Market Size and Demand

The global antidepressant market was valued at approximately USD 16 billion in 2022. Bupropion accounts for about 8% of this market, with annual sales estimated near USD 1.3 billion.

In the United States, prescriptions for bupropion extended-release formulations accounted for roughly 15 million prescriptions in 2022, with a compound annual growth rate (CAGR) of 3% over the past five years.

Competition Landscape

The NDC code indicates a generic product. Major competitors include:

  • Brand: Wellbutrin SR (GlaxoSmithKline, now involved in generic licensing)
  • Generics: Multiple manufacturers (Amneal, Mylan, Teva)

Market entry barriers are low; multiple manufacturers compete on price, with few patent restrictions due to expiration.

Regulatory Environment

The original patent for Wellbutrin SR expired in 2011. Since then, generics have dominated the market. Continued biosimilar or specialty formulations are not prevalent for this drug class.

Price Trends and Projections

Historical Pricing Data

Year Average Wholesale Price (AWP) per 100 mg tablet Notes
2020 USD 0.25 Sustained competition keeps prices low
2021 USD 0.23 Slight decrease, volume-driven
2022 USD 0.20 Price stabilizes under increased competition

Current Price (2023)

The average market price for the generic 100 mg extended-release tablet is approximately USD 0.20 per tablet at wholesale levels. Retail prices are typically 15–30% higher.

Price Projections (2024-2028)

Year Estimated AWP per 100 mg tablet Assumptions
2024 USD 0.19 Market saturation, stable demand
2025 USD 0.18 Increased manufacturing efficiency
2026 USD 0.17 Entry of price-competitor generics, further competition
2027 USD 0.16 Ongoing volume growth, no new formulations
2028 USD 0.15 Marginal price reduction, price wars persist

Influencing Factors

  • Market competition: Intensifies with new generics, driving prices downward.
  • Manufacturing costs: Slight declines due to economies of scale and supply chain maturity.
  • Regulatory activities: No major new regulations expected; patent litigation minimal.
  • Prescriber trends: Steady demand for depression treatment continues.

Revenue Forecasts

Assuming an average of 15 million prescriptions annually in the US, with approximately 90 tablets per prescription:

Year Projected Prescriptions Revenue (USD, at USD 0.20 per tablet)
2023 15 million USD 540 million
2024 15.5 million USD 558 million
2025 16 million USD 576 million
2026 16.5 million USD 594 million
2027 17 million USD 612 million
2028 17.5 million USD 630 million

Note

Prices are for wholesale levels; retail prices are approximately 20–30% higher, impacting end-consumer costs more than manufacturer revenues.

Key Market Drivers

  • Growing prevalence of depression and smoking cessation programs.
  • Cost-effective generics eroding branded sales.
  • Prescriber preference for extended-release formulations based on patient compliance.

Potential Risks

  • Market saturation from multiple generics.
  • Regulatory changes restricting off-label uses.
  • Price erosion due to increased competition.

Key Takeaways

  • The market for NDC 71093-0138 is mature, with stable demand.
  • Prices are declining gradually, with projected median prices of USD 0.15–0.19 per 100 mg tablet by 2028.
  • Revenues will predominantly rely on volume growth, which remains modest.
  • Competition is likely to keep profit margins compressed.

FAQs

What factors influence the price of the generic bupropion product?

Market competition, manufacturing costs, supply chain dynamics, and regulatory policies are primary influences.

How does the expiration of patent rights affect pricing?

Patent expiry opens the market to generic competitors, leading to price reductions driven by increased competition.

Are there upcoming regulatory changes that could impact this drug?

No significant regulatory changes are anticipated for this drug class within the forecast period.

What is the potential of biosimilars or novel formulations?

Biosimilars are not applicable; no new formulations are currently in advanced development stages.

How does market size impact potential profitability?

A larger prescription volume stabilizes revenues even as unit prices decline, maintaining profitability for established manufacturers.

References

[1] IQVIA. (2022). Prescription Data and Market Trends.
[2] Evaluate Pharma. (2022). Global antidepressant market report.
[3] U.S. Food & Drug Administration. (2021). Patent Expiry and Generic Entry Data.
[4] Medications and Pricing Data (2023). Wholesaler and Retail Price Reports.
[5] IMS Health. (2021). Pharmaceutical Market Dynamics.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.